

Date: May 25, 2026

Ref. No.: KDL/SE/012/2026-27

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	---

Dear Sir/Madam,

Sub: Press Release – Audited Financial Results (Standalone and Consolidated) for the quarter and Year ended March 31, 2026.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the audited (Standalone and Consolidated) Financial Results for the quarter and year ended March 31, 2026.

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

Mr. Yash Mutha — Managing Director

"FY2026 marks a year of deliberate and disciplined investment into the long-term architecture of Krsnaa Diagnostics, and the results reflect both the strength of our operating model and the early dividends of our strategic initiatives. On a consolidated basis, we achieved revenue of ₹7,728 million with reported Profit After Tax growing a robust 31% to ₹1,014 million, the highest reported PAT in the Company's history since listing. The reported PAT includes fair valuation gain of the investment in Apulki Healthcare Private Limited, amounting to ₹221.75 million.

The Diluted EPS of ₹30.88 is a 31% improvement over the prior year. Our operating cash flows strengthened significantly to ₹1,431 million in FY2026 compared to ₹873 million in FY2025, an improvement of approximately 64% year-on-year, demonstrating the structural improvement in our collections framework and working capital management.

The Board has recommended a final dividend of ₹2/- per share of face value ₹5/-, and with a well-defined and well-funded growth roadmap anchored in long-term PPP contracts, a rapidly scaling B2C vertical, and a transformative entry into tertiary care through Apulki Healthcare, we remain deeply committed to building a platform that delivers enduring and compounding value to all our stakeholders."

Mr. Mitesh Dave — Group CEO

"FY2026 represents a pivotal inflection point in Krsnaa Diagnostics' growth journey, marked not only by strong headline financial performance but more significantly by the accelerated emergence of our retail diagnostics vertical, Krsnaa Retail Private Limited, as a structurally important and independently scalable growth engine for the Group. Within just twelve months of focused scaling, our retail vertical delivered a 8 times jump in revenue and a 7 times surge in touchpoints, expanding to 3,500 locations across 5 states, a pace of growth that firmly establishes Krsnaa Retail as one of the country's most formidable retail diagnostics growth stories.

As we enter FY2027, we remain focused on disciplined execution, transparency, and strong governance standards, while continuing to uphold the trust placed in us by our investors, partners, and patients."